Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
Autore:
Kiyoi, H; Naoe, T; Nakano, Y; Yokota, S; Minami, S; Miyawaki, S; Asou, N; Kuriyama, K; Jinnai, I; Shimazaki, C; Akiyama, H; Saito, K; Oh, H; Motoji, T; Omoto, E; Saito, H; Ohno, R; Ueda, R;
Indirizzi:
Nagoya Univ, Sch Med, Dept Infect Dis, Nagoya, Aichi 4668560, Japan NagoyaUniv Nagoya Aichi Japan 4668560 Dis, Nagoya, Aichi 4668560, Japan Kyoto Prefectural Univ Med, Dept Med 2, Kyoto 602, Japan Kyoto PrefecturalUniv Med Kyoto Japan 602 Dept Med 2, Kyoto 602, Japan Kyoto Prefectural Univ Med, Dept Med 3, Kyoto 602, Japan Kyoto PrefecturalUniv Med Kyoto Japan 602 Dept Med 3, Kyoto 602, Japan Japanese Res Cross, Nagoya Hosp 1, Dept Med, Nagoya, Aichi, Japan JapaneseRes Cross Nagoya Aichi Japan 1, Dept Med, Nagoya, Aichi, Japan Kumamoto Univ, Sch Med, Dept Internal Med 2, Kumamoto 860, Japan Kumamoto Univ Kumamoto Japan 860 ept Internal Med 2, Kumamoto 860, Japan Nagasaki Univ, Inst Atom Dis, Dept Hematol, Nagasaki, Japan Nagasaki UnivNagasaki Japan st Atom Dis, Dept Hematol, Nagasaki, Japan Saitama Med Sch, Dept Internal Med 1, Moroyama, Saitama, Japan Saitama MedSch Moroyama Saitama Japan l Med 1, Moroyama, Saitama, Japan Tokyo Metropolitan Komagome Hosp, Dept Hematol, Tokyo, Japan Tokyo Metropolitan Komagome Hosp Tokyo Japan Dept Hematol, Tokyo, Japan Dokkyo Univ, Sch Med, Dept Internal Med 3, Mibu, Tochigi, Japan Dokkyo Univ Mibu Tochigi Japan Dept Internal Med 3, Mibu, Tochigi, Japan Chiba Univ, Sch Med, Dept Internal Med 2, Chiba 280, Japan Chiba Univ Chiba Japan 280 ch Med, Dept Internal Med 2, Chiba 280, Japan Tokyo Womens Med Coll, Dept Hematol, Tokyo 162, Japan Tokyo Womens Med Coll Tokyo Japan 162 ll, Dept Hematol, Tokyo 162, Japan Okayama Univ, Sch Med, Dept Med, Okayama 700, Japan Okayama Univ OkayamaJapan 700 iv, Sch Med, Dept Med, Okayama 700, Japan Hamamatsu Univ, Sch Med, Dept Med 3, Hamamatsu, Shizuoka 43131, Japan Hamamatsu Univ Hamamatsu Shizuoka Japan 43131 atsu, Shizuoka 43131, Japan Nagoya City Univ, Sch Med, Dept Internal Med 2, Nagoya, Aichi 467, Japan Nagoya City Univ Nagoya Aichi Japan 467 l Med 2, Nagoya, Aichi 467, Japan
Titolo Testata:
BLOOD
fascicolo: 9, volume: 93, anno: 1999,
pagine: 3074 - 3080
SICI:
0006-4971(19990501)93:9<3074:PIOFAN>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
INTERNAL TANDEM DUPLICATION; MAINTENANCE INTENSIFICATION THERAPY; ACUTE PROMYELOCYTIC LEUKEMIA; CLINICAL-SIGNIFICANCE; HEMATOPOIETIC-CELLS; POINT MUTATIONS; LIGAND; PROLIFERATION; MALIGNANCIES; EXPRESSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Naoe, T Nagoya Univ, Sch Med, Dept Infect Dis, Nagoya, Aichi 4668560, Japan Nagoya Univ Nagoya Aichi Japan 4668560 goya, Aichi 4668560, Japan
Citazione:
H. Kiyoi et al., "Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia", BLOOD, 93(9), 1999, pp. 3074-3080

Abstract

Internal tandem duplication of the FLT3 gene and point mutations of the N-RAS gene are the most frequent somatic mutations causing aberrant signal-transduction in acute myeloid leukemia (AML). However, their prognostic importance is unclear. In this study, their prognostic significance was analyzedin 201 newly diagnosed patients with de novo AML except acute promyelocytic leukemia. Three patients had mutations in both genes, 43 had only the FLT3 gene mutation, 25 had only the N-RAS gene mutation, and 130 had neither. These mutations seemed to occur independently. Both mutations were related to high peripheral white blood cell counts, and the FLT3 gene mutation was infrequently observed in the French-American-British (FAB)-M2 type. AML cases with wild FLT3/mutant N-RAS had a lower complete remission (CR) rate than those with wild FLT3/wild N-RAS, whereas the presence of mutant FLT3 did not affect the CR rate. Univariate analysis showed that unfavorable prognostic factors for overall survival were age 60 years or older (P = .0002), cytogenetic data (P = .002), FAB types other than M2 (P = .002), leukocytosisover 100 +/- 10(9)/L (P = .003), and the FLT3 gene mutation (P = .004). However, the N-RAS gene mutation was only a marginal prognostic factor (P = .06). For the subjects under 60 years old, multivariate analysis showed thatthe FLT3 gene mutation was the strongest prognostic factor (P = .008) for overall survival. The FLT3 gene mutation, whose presence is detectable onlyby genomic polymerase chain reaction amplification and gel electrophoresis, might serve as an important molecular marker to predict the prognosis of patients with AML. (C) 1999 by The American Society of Hematology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 20:51:26